Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 2—February 2011
Dispatch

Novel HIV-1 Recombinant Forms in Antenatal Cohort, Montreal, Quebec, Canada

Mathieu Quesnel-Vallières, Iman Kouzayha, Evelyne Tran, Issatou Barry, Charlène Lasgi, Natacha Merindol, Vanessa Monteil, Doris G. Ransy, Marc Boucher, Normand Lapointe, and Hugo SoudeynsComments to Author 
Author affiliations: Author affiliations: Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada (M. Quesnel-Vallières, I. Kouzayha, E. Tran, I. Barry, C. Lasgi, N. Merindol, V. Monteil, D.G. Ransy, M. Boucher, N. Lapointe, H. Soudeyns); Université de Montréal, Montreal (M. Quesnel-Vallières, I. Kouzayha, E. Tran, I. Barry, N. Merindol, D.G. Ransy, M. Boucher, N. Lapointe, H. Soudeyns); Université Pierre et Marie Curie, Paris, France (C. Lasgi)

Main Article

Table

Virologic and immunologic parameters in patients participating in antenatal cohort, Canada*

Patient Age, y CD4 count, cells/mm3 Viral load, RNA copies/mL Antiretroviral treatment
TV721 33.2 210 164 AZT-3TC-NVP
TV725 30.1 816 739 None
TV749 34.1 198 23,369 AZT-3TC-NFV
TV919 34.0 420 1,910 AZT-3TC-NFV

*AZT, zidovudine; 3TC, lamivudine; NVP, nevirapine; NFV, nelfinavir.

Main Article

Page created: July 08, 2011
Page updated: July 08, 2011
Page reviewed: July 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external